ISRCTN67519330
Completed
Not Applicable
Randomised double-blind placebo controlled study to determine whether the use of selective digestive decontamination pastilles reduces radiation mucositis
K Co-ordinating Committee for Cancer Research (UKCCCR)0 sites0 target enrollmentJuly 1, 2001
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Head and neck
- Sponsor
- K Co-ordinating Committee for Cancer Research (UKCCCR)
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients with head and neck cancer receiving potentially curative doses of radiotherapy
- •2\. Eligible patients may have squamous carcinoma, adenocarcinoma or salivary tumours arising in the oral cavity, nas \-oro, or hypopharynx, larynx and paranasal sinuses
- •3\. Stages T1\-T4
- •4\. No allergy to Polymyxin E, Tobramycin or Amphotericin B
- •5\. No pre\-existing oral or oropharyngeal infection
Exclusion Criteria
- •Not provided at time of registration
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 3
Antiretroviral therapy intensification with raltegravir and/or hyper-immune bovine colostrum in Human Immunodeficiency Virus-1 (HIV-1) infected patients with suboptimal immunological responseHuman Immunodeficiency Virus (HIV)InfectionInfection - Acquired immune deficiency syndrome (AIDS / HIV)ACTRN12609000575235niversity of New South Wales (UNSW)72
Active, not recruiting
Phase 1
Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD – The ABACOPD StudyMedDRA version: 19.0 Level: LLT Classification code 10010953 Term: COPD exacerbation System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2012-003234-16-DEHannover Medical School represented by Hannover Clinical Trial Center GmbH980
Completed
Phase 3
Double-blind placebo-controlled randomized study to determine the effectiveness of magnesium oxide to reduce the prostate motion.prostate cancerprostate carcinoma10038597NL-OMON31671niversitair Medisch Centrum Utrecht92
Active, not recruiting
Not Applicable
Double-blind placebo-controlled randomized study to determine the effectiveness of magnesium oxide to reduce the prostate motion. - Magnesium oxide to reduce prostate motioProstate cancer patients who are being treated with external beam radiotherapy using fiducial marker-based position verification.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2007-007072-42-NLniversity Medical Center Utrecht
Completed
Phase 2
Randomised Double Blind Placebo Controlled Study to Determine the Effects of Vitamin D supplementation on Platelet and Vascular function in patients with Vitamin D insufficiency and known Coronary artery or peripheral vascular diseaseCoronary artery diseaseperipheral vascular diseaseCardiovascular - Other cardiovascular diseasesACTRN12612001221842Alfred Health40